It is believed that nitroglycerin causes vasodilatation by interacting with sulfhydryl groups present in vascular smooth muscle. This study was performed to assess whether methionine, an amino acid capable of increasing sulfhydryl availability, would potentiate the hemodynamic effects of nitroglycerin. Nitroglycerin was initially infused in incremental doses from 1 to 50 ,ug/ min in all patients to determine the dose required to reduce mean arterial pressure by 10% and pulmonary capillary wedge pressure by 30%. After a washout period, 10 patients received 5 g methionine i.v. and five patients received an equal volume of 5% dextrose in water (control). Nitroglycerin dose titration was then repeated. Methionine alone induced no hemodynamic effects, but after methionine infusion, there was a significant reduction in the nitroglycerin infusion rate required to reach each hemodynamic endpoint (p<0.01). In the control group, there was no significant change in responsiveness to nitroglycerin between infusions. Thus, methionine potentiates the hemodynamic efrects of acutely administered intravenous nitroglycerin. (Circulation 1988; 78:640-645) itroglycerin has been widely used for over a century as an antianginal agent' and recently in patients with congestive heart failure.2 The mechanism of action of nitroglycerin is not fully understood; however, it is believed that nitrates cause vasodilatation by interacting with sulfhydryl groups present in vascular smooth muscle. Needleman et al34 first reported the sulfhydryl group requirement for the relaxation of vascular smooth muscle and their interaction with organic nitrates. Ignarro et a15 proposed that nitrates combine with sulfhydryl groups present in vascular smooth muscle to form S-nitrosothiols. These in turn activate guanylate cyclase, which stimulates the production of cyclic guanosine monophosphate (cGMP), which is known to mediate the relaxation of vascular smooth muscle. The depletion of intracellular stores of sulfhydryl groups has been suggested as the mechanism of tolerance to organic nitrates. According to this hypothesis, increasing sulfhydryl group availability may increase the vasodilatory effects of nitroglycerin.
Several investigators6-11 have previously demonstrated that N-acetylcysteine, a donor of reduced sulfhydryl groups, can potentiate the hemodynamic effects of nitroglycerin and, in some cases, partially reverse the attenuation of these effects after prolonged nitroglycerin administration. It has been suggested that the concomitant administration of a sulfhydryl group donor with nitroglycerin may prevent the attenuation of the hemodynamic and therapeutic effects seen with chronic therapy. 1 l N-Acetylcysteine is a noxious substance (attributable to its sulfhydryl group) and is often poorly tolerated by mouth when administered over a prolonged period of time.12'13 It would thus not be well suited for chronic use.
This study was performed to assess whether methionine, an essential amino acid capable of augmenting sulfhydryl group availability, would also potentiate the vasodilatory effects of acutely administered intravenous nitroglycerin. Methionine has been widely used to treat acetaminophen overdose with efficacy equal to that of N-acetylcysteine but with better tolerance when taken orally. [14] [15] [16] 
Materials and Methods Patient Population
The study population was composed of 15 patients (12 men, three women) suspected of having coronary artery disease who were undergoing routine cardiac catheterization for diagnostic indications.
Written informed consent for this study was obtained before catheterization, and the protocol was approved by the investigational review board of the George Washington University Medical Center. Exclusion criteria included left main coronary artery stenosis, significant valvular heart disease, a mean arterial pressure of less than 75 mm Hg, or a capillary wedge pressure of less than 5 mm Hg. All long-acting nitrate preparations were discontinued 24 hours before study and short-acting nitrates were withheld for the 12 hours before study.
Protocol
All patients underwent left and right heart catheterization with coronary arteriography and left ventriculography from the femoral approach. lohexol (Omnipaque 350) was used as the intravenous contrast medium. At the conclusion of the routine cardiac catheterization, a 7F Swan-Ganz catheter was advanced to the pulmonary artery and baseline pulmonary artery and pulmonary capillary wedge (PCW) pressures were recorded over a 1-minute period. Femoral artery pressure was measured via the side arm of a 7F sheath in the femoral artery.
Intravenous nitroglycerin infusion was begun at 1 gg/min via a continuous infusion pump into the side port of an 8F sheath in the femoral vein with vented nitroglycerin tubing. The infusion rate of nitroglycerin was increased every 5 minutes after the recording of mean arterial (MAP) and PCW pressures. Incremental dosing was at 1, 2.5, 5, 10, 25, and 50 jig/min. Nitroglycerin infusion was discontinued when more than 10% reduction in MAP or more than 30% reduction in PCW pressure occurred.
After a 5-minute washout period, 10 patients received 5 g methionine i.v. in 200 ml 5% dextrose in water over 10 minutes and five patients served as controls receiving a placebo dose of 200 ml of 5% dextrose in water. Randomization was carried out in a 2: 1 unblinded fashion. Five minutes after this infusion, incremental nitroglycerin dose titration was again carried out with the same methodology. Drugs The nitroglycerin infusion was prepared with 5 mg nitroglycerin in 500 ml 5% dextrose in water (10 ,ug/ml) in glass bottles to allow for a wide range of dosing at acceptable infusion rates (6-300 ml/hr). Fifty milliliters of solution was run through the i.v. tubing and discarded to minimize absorption.
The methionine infusion was prepared from pharmaceutical-grade pure L-methionine to yield a 2.5% solution in 5% dextrose in water and was microfiltered via 0.22-,um millipore filtration.
Statistical Analysis
The predicted nitroglycerin infusion rate required to reach a hemodynamic endpoint (10%o reduction of MAP and a 30% reduction of PCW pressure) was determined by linear regression. This technique was applied to the data (MAP and PCW pressure) recorded during the study at each incremental nitroglycerin infusion rate. That rate that would have led to exactly a 10% reduction in mean arterial pressure and a 30% reduction in pulmonary capillary wedge pressure were obtained for analysis from the regression. All of the nitroglycerin infusion rate endpoints presented are the values derived from this linear regression. Group comparisons of the baseline hemodynamic variables and patient characteristics were assessed by two-tailed, unpaired Student's t tests. x2 analysis was applied to categorical data. The percent change in nitroglycerin infusion rate listed in Table 3 is expressed as the percentage of the first nitroglycerin infusion rate required to reach the same hemodynamic endpoint during the second nitroglycerin infusion. Statistical comparison of the nitroglycerin infusion rate required to reach the hemodynamic endpoints before and after either methionine or 5% dextrose in water was performed by a repeatedmeasures analysis of variance F test to assess group and order effects. Results are expressed as the mean ± SEM, and for all analyses, psO.O5 was considered significant.
Results
Patient characteristics and baseline hemodynamic values for the two groups of patients are presented in Table 1 . Selective coronary arteriography revealed that three patients in the methionine group and two patients in the control group had no significant coronary artery disease (defined as -50% stenosis in a major epicardial coronary artery). Three patients in the methionine group had singlevessel disease, two patients had two-vessel disease, and two patients had triple-vessel disease. This distribution was comparable to that of two patients with single-vessel disease and one patient with triple-vessel disease in the control group (p = NS).
There was no significant difference between the methionine and control patients with respect to age, sex, cardiac index, baseline MAP, or baseline PCW pressure. Both groups of patients used similar concomitant cardiac medications including betablockers (atenolol in two patients in methionine group), calcium channel blockers (diltiazem in six methionine patients and three control patients and verapamil in one control patient), and long-acting nitroglycerin preparations (three methionine patients and one control patient).
The hemodynamic values (MAP and PCW) before the first nitroglycerin infusion (baseline) and after the infusion of either methionine or 5% dextrose in water but before the second nitroglycerin infusion revealed no statistically significant change for either group (Table 2 ). Methionine thus had no hemodynamic effect in the absence of nitroglycerin. The nitroglycerin infusion rates required to reach the hemodynamic endpoints of a 10% reduction in MAP and a 30% reduction in PCW during the first nitro-glycerin infusion varied from 7.2 to 73 gg/min. There was no statistically significant difference between the methionine and control patients with respect to this infusion rate (Table 3) for either a 10% reduction in MAP (40.7 ±6.1 vs. 24.5 ±5.3) or a 30% reduction in PCW (27.1 + 4.2 vs. 22.0 ± 5.9).
After methionine infusion, every patient demonstrated a diminished nitroglycerin requirement to reach the hemodynamic endpoints of a 10% reduction in MAP (p<0.01, Figure 1 ) and a 30% reduction in PCW (p<0.01, Figure 2 ). In the control group, there was no significant difference in the required nitroglycerin infusion rate after 5% dextrose in water.
A repeated-measures analysis of variance to test for group and order effects revealed a statistically significant difference in the required nitroglycerin infusion rate to reach both a 10% reduction in MAP (p<0.01) and a 30% reduction in PCW (p<0.02) in the methionine group relative to the control group after methionine or 5% dextrose in water. This significant difference was derived from the significant reduction in the required nitroglycerin infusion rate after methionine administration.
All patients enrolled in the study completed the study protocol and methionine produced no adverse effects. 10% MAP, NTG infusion rate in ,g/min to lower baseline MAP by 10%; 30% PCW, NTG infusion rate in ,ug/min to lower baseline PCW by 30%; MAP, mean arterial pressure; PCW, pulmonary capillary wedge pressure.
All values derived from linear regression. *Percent of first nitroglycerin infusion required to achieve hemodynamic endpoint during second infusion.
Methionine Baseline
Post-Meth Control r = p=ns-1 FIGURE 1. Plots of nitroglycerin (NTG) infusion rate to achieve a 10% reduction in mean arterial pressure (MAP) before (baseline) and after either methionine (Meth) or 5% dextrose in water (D5W). Each line represents the datafrom one patient and the mean±SD is displayed with open circles on either side of each set of lines.
Baseline Post-D5W Discussion The mechanism of nitroglycerin-mediated vasodilatation has been shown to require sulfhydryl groups present in vascular smooth muscle, likely in the form of cysteine.3-5 This finding has been supported by studies in which N-acetylcysteine, a source ofreduced sulfhydryl groups, has been shown to potentiate the hemodynamic effects of nitroglycerin as well as partially reverse nitroglycerin tolerance after chronic administration. [6] [7] [8] [9] [10] [11] Horowitz et a18 were the first to demonstrate the ability of N-acetylcysteine to potentiate the hemodynamic effects of acutely administered intravenous nitroglycerin in humans. Torresi et a16 later demonstrated that N-acetylcysteine partially prevented nitroglycerin tolerance in vitro with bovine coronary artery rings preincubated in nitroglycerin and Nacetylcysteine when compared with preincubation in nitroglycerin alone. Several authors9-11 have shown that nitrate tolerance in humans could be reversed, in part, by administering N-acetylcysteine after chronic nitrate therapy.
Methionine
The results of this study demonstrate that methionine also potentiates the hemodynamic effects of acutely administered intravenous nitroglycerin. The nitroglycerin infusion rate required to reach the hemodynamic endpoints of a 10% reduction in MAP and a 30% reduction in PCW pressure were significantly diminished after methionine relative to the control group. In addition, every patient in the methionine group was documented to have a diminished nitroglycerin requirement after methionine compared with their first nitroglycerin infusion. Those patients initially with the greatest nitroglycerin requirement to reach hemodynamic endpoints exhibited the most dramatic response to methionine. A relative sulfhydryl deficiency in these patients would be a possible explanation for this observed nitroglycerin resistance and methionine sensitivity, however, no data is available to confirm this theory. This study design was similar to that of Horowitz et al,8 and the amount of hemodynamic potentiation as measured by the reduced nitroglycerin dose requirement to achieve endpoints was similar for methionine and N-acetylcysteine. Methionine contains no sulfihydryl groups but is a precursor of cysteine ( Figure 3 ). In normal amino acid metabolism, the sulfur atom of cysteine is obtained from the essential amino acid methionine. If there are sufficient dietary sources of methionine, no additional dietary cysteine is needed. '7The first step in this process involves the demethylation of methionine to homocysteine via the intermediate forms of S-adenosylmethionine and S-adenosylhomocysteine. Homocysteine then combines with serine to yield cystathionine in a reaction catalyzed by cystathionine ,B-synthetase, a pyridoxal phosphate requiring enzyme. Finally, cystathionine ylyase catalyses the cleavage of cystathionine to cysteine and a-ketobutyrate. 1718 Genetic defects in cystathionine f-synthetase results in homocystinuria, a metabolic disease known to be associated with premature arteriosclerosis and thromboembolic events. It has been suggested that partial cystathionine p-synthetase deficiency without evidence of homocystinuria may predispose to premature peripheral vascular disease as well, with the estimated population at risk as high as 3 million Americans. 19, 20 Our results further support the hypothesis that nitroglycerin-mediated vasodilatation requires sulfhydryl groups. Methionine alone had no hemodynamic effects in our study population and is not known to have any direct interaction with nitroglycerin. One may speculate that conversion of methionine to cysteine provided additional reduced sulfhydryl groups by which additional S-nitrosothiols could be formed ultimately leading to increased cGMP levels.
It is uncertain whether the addition of sulfhydryl groups alone during chronic nitrate therapy will completely prevent the tolerance to hemodynamic effects that is now well established. N-Acetylcysteine has been successful in partial reversal of tolerance, how-ever, this drug is limited for chronic use attributable to the high frequency of gastrointestinal intolerance when taken chronically. Miller et al'3 reported that 43% of patients receiving 15 or more doses of N-acetylcysteine experienced diarrhea, and 51% experienced nausea and vomiting. Our results suggest that methionine is another sulfhydryl donor by virtue of its conversion to cysteine. It is well tolerated when taken chronically,' and these data provide a basis for evaluating this substance for this indication. The problem of methionine intolerance thought to be present in as much as 14% of the population can be obviated by the screening procedures described previously.20 Further investigation is required for the complete understanding of both the mechanisms of action and those of tolerance to the hemodynamic effects of nitroglycerin.
